Michael Heltzen, CEO of eXoZymes, joins Grow Everything to explain how cell free biomanufacturing is opening new possibilities for natural products, nutraceuticals, and medicines. Michael shares why engineered enzymes can make high purity molecules without relying on living cells, how eXoZymes moved its NCT program from discovery toward commercial manufacturing in less than two years, and why its capital light partnership model is central to scaling impact. The conversation also explores AI guided enzyme design, digital twins for manufacturing, rare cannabinoids, downstream processing, and the disciplined focus required to turn a broad biotechnology platform into real products.
Episode also available via Spotify and Apple.
eXoZymes Safe Harbor
This content includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “potential,” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this content regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.